Expression Of CD133Molecules In Childhood Acute Leukemia And Its Clinical Significance

Objective To explore relationship between the expression of CD133and clinicalprognostic factors and minimal residual disease (MRD) in childhood acute leukemia (AL)before and after treatment, expression of CD133of bone marrow (BM) mononuclear cells(mononuclear cells, MNCs) in AL was analysed.Methods1) Expression of CD133-1/CD133-2was detected by flow cytometryfrom BM MNCs in65cases of newly diagnosed AL,35cases after inductionchemotheraphy and16cases after12week’s treatment. Expression levels of at differenttime point was compared. Relationship between quantity level of MRD in childhoodB-ALL after33days treament and expression of CD133was evaluated.2) CD133-1andCD133-2mRNA was detected by RT-PCR assay from41different samples in65cases.Correlation of the level of CD133mRNA with expression of CD133was assessed.Results1) There was no relevance between expression of CD133and sex，age,white blood cell count, percentage of bone marrow blast cells, LDH’s level, FAB subtype,cytogenetics, fusion gene, risk stratification, and the CR rate in childhood AL.2)Correlation of expression of CD133and CD34in newly diagnosed AL patients: there wasno significant correlation between expression of CD133and CD34in ALL, while therewas significant correlation between expression of CD133and CD34in AML.3) ALL: ALLnewly diagnosed group, expression of CD133-1was positive in19cases (39.6%) from48cases, and expression of CD133-2in30cases (62.5%) was positive (P <0.05). After33days’ treatment, expression of CD133-1in2cases (6.9%) from29cases was positive, andexpression of CD133-2in23cases (79.3%) was positive (P <0.05). After12weeks’treatment, expression of CD133-1in2cases (13.3%) from15cases was positive, andexpression of CD133-2in9cases (60.0%) was positive (P <0.05). The expression ofCD133-2and level of MRD in B-ALL was moderate correlation on the33rd day of the first treatment (r=0.412, P=0.041).4) AML: AML newly diagnosed group, expression ofCD133-1in12cases (63.2%) from19cases was positive, and expression of CD133-2in11cases (57.9%) was positive (P>0.05). After33days’ treatment, expression of CD133-1in3cases (50.0%) from6cases was positive, and expression of CD133-2in5cases(83.3%)were positive (P>0.05).5) Comparison of expression of CD133-1and CD133-2at different time points of and contrast in itself: expressions of CD133-1and CD133-2innewly diagnosed ALL and expression of CD133-1in newly diagnosed AML wassignificantly higher than those after chemotherapy, compared to untreated groupexpression of CD133-2after30days’ treatment in AML increased. Expressions ofCD133-1and CD133-2in newly diagnosed ALL group had significant difference whileexpressions of CD133-1and CD133-2in newly diagnosed AML group had no significantdifference.Conclusions1There was no relevance between expression of CD133and sex，age, white blood cell count, percentage of bone marrow blast cells, LDH’s level, FABsubtype, cytogenetics, fusion gene, risk stratification, and the CR rate in childhood AL.2.Compared toALL patients, expression of CD133-1in AML was higher,while expression ofCD133-2had no significant difference.3.ALL:1) Positive expression rates and levels ofCD133-2were higher than those of CD133-1in ALL.2) After induction chemotherapy, theexpression of CD133-1decreased significantly, but was still higher than normal controlgroup;3) With chemotherapy, compared to expression of CD133-1, expression level ofCD133-2decreased slowly;4) There was no correlation between expression of CD133andCD34.4. AML:1) There was no significant difference for positive expression rate andexpression levels between CD133-1and CD133-2in AML;2) After inductionchemotherapy, expressions of CD133-1and CD133-2were varied;3) There wassignificant correlation between expression of CD133and CD34.5. In B-ALL, expressionof CD133-2was significantly related to level of MRD.